Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-10-0644PMID 20937594PMCID PMC2954514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.

  2010cited by this paper
• Preparation of microtubule protein and purified tubulin from bovine brain by cycles of assembly and disassembly and phosphocellulose chromatography.

  2010cited by this paper
• Analysis of dynamic instability of steady-state microtubules in vitro by video-enhanced differential interference contrast microscopy with an appendix by Emin Oroudjev.

  2010cited by this paper
• The Neuroprotective Peptide NAP Does Not Directly Affect Polymerization or Dynamics of Reconstituted Neural Microtubules

  2010cited by this paper
• Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.

  2010cited by this paper
• A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in HER2+ Metastatic Breast Cancer (MBC) Patients Previously Treated with Conventional Chemotherapy, Lapatinib and Trastuzumab.

  2009cited by this paper
• Structural insight into the inhibition of tubulin by vinca domain peptide ligands

  2008cited by this paper
• How do microtubule-targeted drugs work? An overview.

  2007cited by this paper
• Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

  2006cited by this paper
• Development of a Novel Nitro-Derivative of Noscapine for the Potential Treatment of Drug-Resistant Ovarian Cancer and T-Cell Lymphoma

  2006cited by this paper
• Semisynthetic maytansine analogues for the targeted treatment of cancer.

  2006cited by this paper
• Microtubules as a target for anticancer drugs

  2004cited by this paper
• Technology evaluation: cantuzumab mertansine, ImmunoGen.

  2004cited by this paper
• A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors

  2004cited by this paper
• Recent developments in the maytansinoid antitumor agents.

  2004cited by this paper
• Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice

  2004cited by this paper
• Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.

  2002cited by this paper
• Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action.

  1998cited by this paper
• Differential Effects of Vinblastine on Polymerization and Dynamics at Opposite Microtubule Ends*

  1996cited by this paper
• Kinetic stabilization of microtubule dynamics at steady state in vitro by substoichiometric concentrations of tubulin-colchicine complex.

  1995cited by this paper
• Effects of antimitotic agents on tubulin-nucleotide interactions.

  1991cited by this paper
• Binding of vinblastine to stabilized microtubules.

  1989cited by this paper
• Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies

  1988cited by this paper
• Effects of Tau and MAP2 on the interaction of maytansine with tubulin: inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin.

  1985cited by this paper
• Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin.

  1984cited by this paper
• Tubulin-colchicine complexes differentially poison opposite microtubule ends.

  1984cited by this paper
• Interaction of vinblastine with steady-state microtubules in vitro.

  1982cited by this paper
• Binding of maytansinoids to tubulin.

  1981cited by this paper
• Effects of inhibitors of tubulin polymerization on GTP hydrolysis.

  1981cited by this paper
• Maytansine binding to the vinblastine sites of tubulin

  1977cited by this paper
• The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides.

  1977cited by this paper
• Binding of maytansine to rat brain tubulin.

  1976cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Antimitotic activity of the potent tumor inhibitor maytansine.

  1975cited by this paper
• Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus.

  1972cited by this paper
• A graphic method for the determination and presentation of binding parameters in a complex system.

  1967cited by this paper

• Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science

  2026cites this paper
• Mechanisms of resistance to antibody-drug conjugates in breast cancer.

  2026cites this paper
• A strategically designed homogeneous antibody-drug conjugate improves safety and therapeutic index in renal cell carcinoma

  2026cites this paper
• Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas.

  2025cites this paper
• Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions

  2025cites this paper
• Advances in immunoPET/SPECT imaging: The role of Fab and F(ab′)2 fragments in theranostics

  2025cites this paper
• Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges

  2025cites this paper
• Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems

  2025cites this paper
• Methods for the Generation of Single‐Payload Antibody‐Drug Conjugates

  2025cites this paper
• Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy

  2025cites this paper
• A Review on the Microtubule Inhibitory Effects of Active Ingredients Extracted from TCMs and Ethnic Medicines in Cancer Treatment.

  2025cites this paper
• The response regulator CrsR positively regulates ansamitocin P-3 biosynthesis in Actinosynnema pretiosum

  2025cites this paper
• Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy

  2024cites this paper
• Bi-specific antibody engagers for cancer immunotherapy

  2024cites this paper
• 2,3-Dihydroquinazolin-4(1H)-ones and quinazolin-4(3H)-ones as broad-spectrum cytotoxic agents and their impact on tubulin polymerisation.

  2024cites this paper
• Targeted Glioma Therapy—Clinical Trials and Future Directions

  2024cites this paper
• Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities

  2024cites this paper
• Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers

  2024cites this paper
• Empowering lung cancer treatment: Harnessing the potential of natural phytoconstituent‐loaded nanoparticles

  2024cites this paper
• Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts

  2024cites this paper
• Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.

  2024cites this paper
• Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review

  2024cites this paper
• Comprehensive mass spectrometric metabolomic profiling of a chemically diverse collection of plants of the Celastraceae family

  2024cites this paper
• Natural-source Payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions.

  2024cites this paper
• Piperlongumine and its derivatives against cancer: A recent update and future prospective

  2024cites this paper
• Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy

  2024cites this paper
• Successful repositioning of mertansine for improved chemotherapy by combining a polymer prodrug approach and PET imaging.

  2024cites this paper
• Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer

  2024cites this paper
• Resistance to antibody–drug conjugates: A review

  2024cites this paper
• Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.

  2023cites this paper
• METTL7A (TMT1A) and METTL7B (TMT1B) Are Responsible for Alkyl S-Thiol Methyl Transferase Activity in Liver

  2023cites this paper
• HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications.

  2023cites this paper
• Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates

  2023cites this paper
• Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis.

  2023cites this paper
• Transforming a highly toxic agent DM1 into injectable safe nanomedicines via prodrug self-assembly for the treatment of taxane-resistant cancer.

  2023cites this paper
• The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

  2023cites this paper
• Melittin derived peptide-drug conjugate, M-DM1, inhibits tumor progression and induces effector cell infiltration in melanoma by targeting M2 tumor-associated macrophages

  2023cites this paper
• An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia.

  2023cites this paper
• New insights into the anticancer therapeutic potential of maytansine and its derivatives.

  2023cites this paper
• Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4‐Conjugate), Based on an In Vitro–In Vivo Extrapolation Approach

  2023cites this paper
• Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study

  2022cites this paper
• Synthesis and Biological Evaluation of C(13)/C(13′)‐Bis(desmethyl)disorazole Z

  2022cites this paper
• METTL7A and METTL7B are responsible for S-thiol methyl transferase activity in liver

  2022cites this paper
• Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate

  2022cites this paper
• Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer.

  2022cites this paper
• Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor

  2022cites this paper
• Recent Approaches to the Identification of Novel Microtubule-Targeting Agents

  2022cites this paper
• A Review on Mechanistic Insight of Plant Derived Anticancer Bioactive Phytocompounds and Their Structure Activity Relationship

  2022cites this paper
• Potential of antibody–drug conjugates (ADCs) for cancer therapy

  2022cites this paper
• Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.

  2021cites this paper
• Role of Modern Biological Techniques in Evidence-Based Validation of Ayurvedic Herbometallic Preparations

  2021cites this paper
• Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders

  2021cites this paper
• Exploiting endophytic microbes as micro-factories for plant secondary metabolite production

  2021cites this paper
• Design, Synthesis, and In Vitro Evaluation of Tubulin-targeting Dibenzothiazines with Antiproliferative Activity as Novel Heterocycle Building Block.

  2021cites this paper
• Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance

  2021cites this paper
• C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids.

  2021cites this paper
• Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.

  2021cites this paper
• Medicinal Plants with Anti-Leukemic Effects: A Review

  2021cites this paper
• Immunotherapy in endometrial cancer: rationale, practice and perspectives

  2021cites this paper
• Photoactivatable prodrug for simultaneous release of mertansine and CO along with a BODIPY derivative as a luminescent marker in mitochondria: a proof of concept for NIR image-guided cancer therapy

  2020cites this paper
• Endoplasmic reticulum-targeted glutathione and pH dual responsive vitamin lipid nanovesicles for tocopheryl DM1 delivery and cancer therapy.

  2020cites this paper
• Antibody–Drug Conjugates for Cancer Therapy

  2020cites this paper
• Synthesis and biological evaluation of oxazinonaphthalene-3-one derivatives as potential anticancer agents and tubulin inhibitors

  2020cites this paper
• Nano-Delivery Carriers for Enhanced Bioavailability of Antitumor Phytochemicals

  2020cites this paper
• Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes

  2020cites this paper
• A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma.

  2020cites this paper
• Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.

  2020cites this paper
• A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

  2020cites this paper
• Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy

  2020cites this paper
• Antibody-drug conjugates: the new generation of biotechnological therapies against cancer.

  2020cites this paper
• Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer Activity

  2020cites this paper
• Microtubule-targeting agents and their impact on cancer treatment.

  2020cites this paper
• An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities

  2020cites this paper
• A Novel HER2-targeted Antibody–drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels

  2020cites this paper
• Anticuerpos conjugados a fármaco: la nueva generación de terapias biotecnológicas contra el cáncer

  2020cites this paper
• Nanoparticles Encapsulating Nitrosylated Maytansine to Enhance Radiation Therapy.

  2020cites this paper
• ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies.

  2019cites this paper
• Antibody–Drug Conjugates: A Comprehensive Review

  2019cites this paper
• DM1 Loaded Ultrasmall Gold Nanoparticles Display Significant Efficacy and Improved Tolerability in Murine Models of Hepatocellular Carcinoma.

  2019cites this paper
• Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

  2019cites this paper
• Antibody–drug conjugates for ovarian cancer: current clinical development

  2019cites this paper
• Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine

  2019cites this paper
• Antibody‑Drug Conjugates

  2019cites this paper
• Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.

  2019cites this paper
• Systematic identification of regulators of antibody-drug conjugate toxicity using CRISPR-Cas9 screens

  2019cites this paper
• CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity

  2019cites this paper
• Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer

  2018cites this paper
• Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies

  2018cites this paper
• Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy

  2018cites this paper
• Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update

  2018cites this paper
• Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate

  2018cites this paper
• Current scenario and future strategies to fight artemisinin resistance

  2018cites this paper
• Anticancer Activity of Natural Compounds from Plant and Marine Environment

  2018cites this paper
• Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

  2018cites this paper
• Exploring Medicinal Plant Legacy for Drug Discovery in Post-genomic Era

  2018cites this paper
• Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.

  2018cites this paper
• Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.

  2018cites this paper
• Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings

  2018cites this paper
• A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin

  2018cites this paper
• Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer

  2017cites this paper